↓ Skip to main content

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults

Overview of attention for article published in Human vaccines immunotherapeutics, February 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
41 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults
Published in
Human vaccines immunotherapeutics, February 2018
DOI 10.1080/21645515.2017.1415683
Pubmed ID
Authors

Goran Stevanovic, Lidija Lavadinovic, Svetlana Filipovic Vignjevic, Renée Holt, Katarina Ilic, Francesco Berlanda Scorza, Erin Sparrow, Vera Stoiljkovic, Guido Torelli, Tamra Madenwald, Muriel Socquet, Aleksandra Barac, Yordanka Ilieva-Borisova, Mijomir Pelemis, Jorge Flores

Abstract

This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The vaccine was manufactured in eggs by the Torlak Institute of Virology, Vaccines and Sera, Belgrade, Serbia and contained A/H1N1, A/H3N2 and B viruses. The clinical trial took place at the Clinical Center of Serbia in Belgrade. Sixty healthy volunteers, aged 18-45 years, were enrolled in the trial. On the day of immunization, volunteers were randomly assigned to receive either a single dose of the trivalent seasonal influenza vaccine (15 μg of hemagglutinin per strain) or placebo (phosphate-buffered saline). Subjects were monitored for adverse events through a clinical history and physical examination, and blood was taken for testing at screening and on day 8 to assess vaccine safety. Serum samples obtained before and 21 days after immunization were tested for influenza antibody titers using hemagglutination-inhibition (HAI) and microneutralization (MN) tests. No serious adverse events were reported. Pain and tenderness at the injection site were the most commonly reported symptoms in both vaccine and placebo groups. Overall, serum HAI responses of fourfold or greater magnitude were observed to H1, H3, and B antigen in 80%, 75%, and 70% of subjects, respectively. Seroprotection rates as measured by HAI were also high (100%, 100% and 86.67%, respectively, for H1, H3 and B). Thus, Torlak's seasonal trivalent influenza vaccine was not associated with adverse events, was well-tolerated and immunogenic. It should be further evaluated in clinical trials to provide sufficient safety and immunogenicity data for licensing in Serbia.

X Demographics

X Demographics

The data shown below were collected from the profiles of 41 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 5 13%
Student > Bachelor 4 10%
Student > Master 4 10%
Student > Ph. D. Student 3 8%
Professor 2 5%
Other 3 8%
Unknown 18 46%
Readers by discipline Count As %
Medicine and Dentistry 4 10%
Biochemistry, Genetics and Molecular Biology 4 10%
Nursing and Health Professions 3 8%
Social Sciences 2 5%
Agricultural and Biological Sciences 1 3%
Other 4 10%
Unknown 21 54%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2024.
All research outputs
#1,426,421
of 25,564,614 outputs
Outputs from Human vaccines immunotherapeutics
#309
of 3,872 outputs
Outputs of similar age
#30,999
of 344,335 outputs
Outputs of similar age from Human vaccines immunotherapeutics
#9
of 61 outputs
Altmetric has tracked 25,564,614 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,872 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,335 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.